Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

TPST

Tempest Therapeutics Inc

Nov 25 • 04:00PM ET

3.20

-0.97 -23.26 %

Healthcare • Biotechnology • USA • NASD

Peers: IMMP ADAP ATNM AGEN AFMD HOOK KALA COGT ONCY MRKR

| Held by: VTI VXF DFSU DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.10	Insider Own	6.97%	Shs Outstand	4.44M	Perf Week	-65.37%
Market Cap	14.21M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.13M	Perf Month	-70.94%
Enterprise Value	15.10M	PEG	-	EPS next Q	-	Inst Own	6.36%	Short Float	3.78%	Perf Quarter	-70.26%
Income	-36.05M	P/S	-	EPS this Y	-	Inst Trans	-7.65%	Short Ratio	1.92	Perf Half Y	-49.21%
Sales	0.00M	P/B	2.24	EPS next Y	-	ROA	-141.49%	Short Interest	0.16M	Perf YTD	-70.50%
Book/sh	1.43	P/C	1.89	EPS next 5Y	-	ROE	-405.03%	52W High	13.65 -76.56%	Perf Year	-72.45%
Cash/sh	1.69	P/FCF	-	EPS past 3/5Y	41.44% 50.16%	ROIC	-265.02%	52W Low	3.30 -2.99%	Perf 3Y	-85.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	38.40% 14.50%	Perf 5Y	-99.02%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	49.43%	Oper. Margin	-	ATR (14)	0.94	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	22.20	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.30	EPS Q/Q	85.13%	SMA20	-60.89%	Beta	-2.26	Target Price	9.00
Payout	-	Debt/Eq	1.32	Sales Q/Q	-	SMA50	-66.35%	Rel Volume	8.51	Prev Close	4.17
Employees	25	LT Debt/Eq	1.14	Earnings	Nov 05 BMO	SMA200	-63.33%	Avg Volume	81.10K	Price	3.20
IPO	Nov 12, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	689,766	Change	-23.26%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Feb-08-24	Initiated	Jefferies	Buy	$15

Today 08:00AM	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.26%
Nov-19-25 09:00AM	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire) -48.59%
Nov-05-25 08:30AM	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +9.10%
Aug-13-25 08:00AM	Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer (Business Wire) +6.02%
Aug-11-25 04:12PM	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.83% +9.99%
08:00AM	Loading…
Jun-30-25 08:00AM	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China (GlobeNewswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 08:00AM	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock (GlobeNewswire) -15.88%
Jun-06-25 11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 08:00AM	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC (GlobeNewswire) +15.16%
May-13-25 04:28PM	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 04:05PM	Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting (GlobeNewswire) -6.26%
Apr-21-25 08:00AM	Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP (GlobeNewswire)
Apr-10-25 11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks) -18.04%
Apr-09-25 04:30PM	Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value (GlobeNewswire) +9.87%
04:10PM	Loading…
Mar-27-25 04:10PM	Tempest Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.08%
Mar-25-25 04:30PM	Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-13-25 08:00AM	FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Feb-10-25 08:00AM	Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (GlobeNewswire)
Feb-07-25 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 08:00AM	Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) (GlobeNewswire)
Dec-06-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 09:00PM	A Reverse Aging Gurus Trail of Failed Businesses (The Wall Street Journal)
Nov-25-24 04:30PM	Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 04:21PM	Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.50%
08:00AM	Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma (GlobeNewswire)
Oct-10-24 07:01AM	Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial (GlobeNewswire) -18.52%
07:00AM	Tempest Extends Limited Duration Stockholder Rights Plan (GlobeNewswire)
Sep-20-24 04:30PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-24 08:00AM	Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs (GlobeNewswire) -6.62%
08:00AM	Loading…
Sep-05-24 08:00AM	Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.04%
Aug-23-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 08:00AM	Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance (GlobeNewswire)
Aug-15-24 08:00AM	Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma (GlobeNewswire) +30.25%
Aug-08-24 04:56PM	Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -14.18%
Jun-20-24 08:13AM	Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? (InvestorPlace) -29.47%
08:00AM	Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm (GlobeNewswire)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 06:22PM	Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Jun-07-24 04:30AM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-24 08:00AM	Tempest to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 04:29PM	Tempest Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.34%
Apr-26-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 08:00AM	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications (GlobeNewswire) -12.20%
Mar-19-24 09:53PM	TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:25PM	Tempest Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types (GlobeNewswire)
Mar-05-24 04:30PM	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting (GlobeNewswire) +16.09%
Feb-26-24 08:00AM	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-02-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.60%
Dec-01-23 04:15PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 08:00AM	Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.25%
Nov-08-23 05:17PM	Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.74% +16.31%
Oct-12-23 08:25AM	Why Is Tempest Therapeutics (TPST) Stock Down 35% Today? (InvestorPlace) -59.26%
Oct-11-23 04:29PM	TPST Stock: 7 Things to Know About Tempest Therapeutics (InvestorPlace) +3,972.53%
08:01AM	Tempest Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
08:00AM	Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study (GlobeNewswire)
07:41AM	Why Is Tempest Therapeutics (TPST) Stock Up 325% Today? (InvestorPlace)
Oct-10-23 04:05PM	Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Sep-19-23 08:00AM	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Sep-05-23 08:00AM	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:13PM	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Jul-19-23 08:00AM	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together (GlobeNewswire)
May-31-23 04:05PM	Tempest to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.85% -5.88%
May-25-23 05:00PM	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers (GlobeNewswire) -9.76%
May-19-23 04:05PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 04:15PM	Tempest Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 08:00AM	Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire) +23.26%
Apr-27-23 04:58PM	Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Apr-26-23 06:41PM	Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting (GlobeNewswire) -6.74%
Apr-17-23 09:00AM	Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting (GlobeNewswire) +25.42%
Mar-22-23 05:26PM	Tempest Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.52%
Mar-15-23 04:05PM	Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting (GlobeNewswire)
Mar-14-23 04:30PM	Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting (GlobeNewswire) +15.79%
Nov-22-22 04:05PM	Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-10-22 09:00AM	Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer (GlobeNewswire)
Nov-08-22 08:00AM	Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -12.09%
Nov-02-22 08:00AM	Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting (GlobeNewswire) +8.72%
Oct-06-22 08:00AM	Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit (GlobeNewswire)
Sep-07-22 08:00AM	Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +11.40%
Aug-15-22 08:00AM	Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +15.81%
Jul-07-22 08:00AM	Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference (GlobeNewswire) +11.93%
Jun-09-22 08:00AM	Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance (GlobeNewswire)
Jun-06-22 04:05PM	Tempest to Present at the Jefferies Healthcare Conference (GlobeNewswire) -12.50%
May-26-22 04:57PM	Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting (GlobeNewswire) -26.68%
May-13-22 08:00AM	Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.88%
Apr-27-22 10:01AM	Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire) +30.08%
08:00AM	Tempest Announces Private Placement Financing of $15 Million (GlobeNewswire)
Apr-08-22 01:00PM	Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-29-22 04:00PM	Tempest Reports Year End 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.89%
Mar-10-22 08:00AM	Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -9.23%
Mar-08-22 04:30PM	Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-09-22 08:00AM	Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference (GlobeNewswire)
Nov-18-21 08:00AM	Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab (GlobeNewswire)
Nov-12-21 07:00AM	Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer (GlobeNewswire)
Nov-10-21 04:05PM	Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Nov-09-21 08:00AM	Tempest to Present at Two Upcoming Investor Conferences in November (GlobeNewswire)
Nov-08-21 08:00AM	Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495 (GlobeNewswire)

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

TPST

Tempest Therapeutics Inc

Upgrade your FINVIZ experience